Potassium News and Research

RSS

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Older adults taking the antibiotic combination trimethoprim-sulfamethoxazole (TMP-SMX)—widely prescribed for urinary tract infections—are at increased risk of elevated potassium levels, called hyperkalemia, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

2 Jul 2010

Digoxin drug may increase risk of premature death in patients with kidney disease

For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

25 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

In 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the structure of an ion channel his lab had been studying for five years.

24 Jun 2010

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Three leading scientists in the field of cardiac safety in pre-clinical drug development are gathering to discuss Improved Strategies for Pre-clinical Cardiac Testing in a free webinar on June 23 at 11:00 a.m. EDT, sponsored by the Drug Safety Council.

22 Jun 2010

Dietary guideline on sodium puts Americans at risk

The Dietary Guidelines Advisory Committee (DGAC) of the U.S. Department of Health and Human Services and the U.S. Department of Agriculture may increase health risks, including obesity, by ignoring sound science as they announce recommendations to reduce sodium consumption to 1,500 mg per day, says the Salt Institute.

16 Jun 2010

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Sensory-tested flavors for coconut water formulations

WILD Flavors, Inc. continues to be innovative in product and flavoring offerings, and has expanded into the coconut water trend through the research and development of not only flavors that test well in coconut water applications, but in new marketable concepts that utilize coconut water. As consumers grow to love the health benefits of coconut water - so will their taste palettes, especially when paired with WILD's sensory-tested flavors for coconut water formulations.

15 Jun 2010

AACN endorses scientific statement on prevention of TdP

The American Association of Critical-Care Nurses recently endorsed "Prevention of Torsades de Pointes in Hospital Settings," a scientific statement from the American Heart Association, Dallas, and American College of Cardiology Foundation, Washington, D.C.

10 Jun 2010

Penn State study: Young girls who drink soda have less healthy diets through adolescence

Young girls who drink soda have less healthy diets through adolescence than their peers who do not drink soda, according to a Penn State study. The ten-year study showed that girls who drank soda at age five had diets that were less likely to meet nutritional standards for the duration of the study, which ended at age 15. Girls who did not drink soda at age five did not meet certain nutritional requirements, but their diets were healthier.

9 Jun 2010

NYBA recognizes Acorda Therapeutics President with The Cures Start Here Business Leader of the Year Award

Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President and Chief Executive Officer, is the recipient of the New York Biotechnology Association "The Cures Start Here" Business Leader of the Year Award. The award is presented for outstanding service to the patient community and to NYBA.

8 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

Water is essential but electrolyte drinks are needed when exercising in heat

Water is essential when exercising in the heat but it might not be enough to keep you healthy in Houston summers.

5 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Kidney dialysis patients unprepared for disasters: Study

Immediately after Hurricane Katrina in August 2005, the survival of more than 5,800 Gulf Coast kidney dialysis patients was threatened as the storm forced closure of 94 dialysis units. Within a month 148 of these patients had died.

4 Jun 2010

Chocolate milk offers recovery advantage to help repair and rebuild muscles: Researchers

One of the best post-exercise recovery drinks could already be in your refrigerator, according to new research presented at the American College of Sports Medicine conference this week. In a series of four studies, researchers found that chocolate milk offered a recovery advantage to help repair and rebuild muscles, compared to specially designed carbohydrate sports drinks.

3 Jun 2010

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo Company announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets).

2 Jun 2010

Potassium News and Research

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Digoxin drug may increase risk of premature death in patients with kidney disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Dietary guideline on sodium puts Americans at risk

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Sensory-tested flavors for coconut water formulations

AACN endorses scientific statement on prevention of TdP

Penn State study: Young girls who drink soda have less healthy diets through adolescence

NYBA recognizes Acorda Therapeutics President with The Cures Start Here Business Leader of the Year Award

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Water is essential but electrolyte drinks are needed when exercising in heat

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Kidney dialysis patients unprepared for disasters: Study

Chocolate milk offers recovery advantage to help repair and rebuild muscles: Researchers

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News